tradingkey.logo

ARS Pharmaceuticals Inc

SPRY
查看詳細走勢圖
10.030USD
+0.360+3.72%
收盤 02/06, 16:00美東報價延遲15分鐘
991.41M總市值
虧損本益比TTM

ARS Pharmaceuticals Inc

10.030
+0.360+3.72%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.72%

5天

+0.40%

1月

-9.64%

6月

-43.17%

今年開始到現在

-13.91%

1年

-15.86%

查看詳細走勢圖

TradingKey ARS Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

ARS Pharmaceuticals Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名41/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為強力買入。最高目標價為28.17。中期看,股價處於上升通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ARS Pharmaceuticals Inc評分

相關信息

行業排名
41 / 392
全市場排名
147 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

ARS Pharmaceuticals Inc亮點

亮點風險
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
業績高增長
公司營業收入穩步增長,連續3年增長6674.24%
業績增長期
公司處於發展階段,最新年度總收入89.15M美元
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值-12.46,處於3年歷史合理位
機構減倉
最新機構持股88.46M股,環比減少9.88%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉3.50M股
活躍度增加
近期活躍度增加,過去20天平均換手率1.06

分析師目標

基於 6 分析師
強力買入
評級
28.167
目標均價
+177.78%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ARS Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ARS Pharmaceuticals Inc簡介

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
公司代碼SPRY
公司ARS Pharmaceuticals Inc
CEOLowenthal (Richard E)
網址https://ars-pharma.com/
KeyAI